Hutchmed (China) Limited Blocklisting Six Monthly Return (1954L)

TIDMHCM

RNS Number : 1954L

Hutchmed (China) Limited

30 December 2022

Blocklisting Six Monthly Return

Hong Kong, Shanghai, & Florham Park, NJ - Friday, December 30, 2022: HUTCHMED (China) Limited (" HUTCHMED " or the "Company") (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting six monthly return:

 
1.   Name of applicant:            HUTCHMED (China) Limited 
2.   Name of scheme:               (a)  Share Option Scheme conditionally adopted 
                                         by HUTCHMED in 2005 ("2005 HUTCHMED 
                                         Share Option Scheme") 
                                   (b)  Share Option Scheme conditionally adopted 
                                         by HUTCHMED in 2015 ("2015 HUTCHMED 
                                         Share Option Scheme") 
3.   Period of return:             From June 29, 2022 to December 28, 2022 
4.   Balance under scheme          (a)  2005 HUTCHMED Share Option Scheme: 883,300 
      from previous return:              ordinary shares of US$0.1 each 
                                   (b)  2015 HUTCHMED Share Option Scheme: 52,867,578 
                                         ordinary shares of US$0.1 each 
5.   The amount by which           (a)  2005 HUTCHMED Share Option Scheme: Nil 
      the block scheme has 
      been increased, if 
      the scheme has been 
      increased since the 
      date of the last return: 
                                   (b)  2015 HUTCHMED Share Option Scheme: Nil 
 
6.   Number of securities          (a)  2005 HUTCHMED Share Option Scheme: Nil 
      issued/allotted under 
      scheme during period: 
                                   (b)  2015 HUTCHMED Share Option Scheme: 200,000 
7.   Balance under scheme          (a)  2005 HUTCHMED Share Option Scheme: 883,300 
      not yet issued/allotted            ordinary shares of US$0.1 each 
      at end of the period: 
                                   (b)  2015 HUTCHMED Share Option Scheme: 52,667,578 
                                         ordinary shares of US$0.1 each 
8.   Number and class of           25,198,880 ordinary shares of US$0.1 each 
      securities originally         admitted on June 17, 2019 (to replace the 
      listed and the date           Company's previous block admission schemes 
      of admission:                 following the Company's share subdivision 
                                    which took effect on May 30, 2019) 
 
 
 
 
9.   Total number of securities    864,775,340 ordinary shares of US$0.1 each 
      in issue at the end 
      of the period: 
Name of contact:                   Weiguo Su 
Address of contact:                Level 18, The Metropolis Tower, 10 Metropolis 
                                    Drive, Hung Hom, Kowloon, Hong Kong 
Telephone number of contact:       [phone] 
 

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has about 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception HUTCHMED has been focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch--med.com or follow us on LinkedIn .

CONTACTS

 
Investor Enquiries 
  Mark Lee, Senior Vice President        [phone] 
  Annie Cheng, Vice President            [phone] 
 
Media Enquiries 
  Americas - Brad Miles, Solebury        [phone] (Mobile) | [e-mail] 
  Europe - Ben Atwell / Alex Shaw, FTI   [phone] / [phone] (Mobile) / [phone] (Mobile) | 
                                         [e-mail] 
  Asia - Zhou Yi, Brunswick              [phone] (Mobile) | [e-mail] 
 
Nominated Advisor 
  Atholl Tweedie / Freddy Crossley, 
   Panmure Gordon (UK) Limited           [phone] 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BLREANANAFNAFEA

(END) Dow Jones Newswires

December 30, 2022 03:30 ET (08:30 GMT)